Empagliflozin slows renal disease progression in type 2 diabetes

Empagliflozin was associated with a significant 39% decrease in risk of new or worsening nephropathy, compared with placebo among adults with type 2 diabetes at high risk for cardiovascular events,...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news